Developer docs
API playgroundTry for free, no card

Search company profiles

Exalenz Bioscience

Full company profile

uuid003efl4

Namestring
Exalenz Bioscience
Legal namestring
Exalenz Bioscience Ltd.
Websiteurl
exalenz.com
Company typeenum
Private
Founded yearint
2006
Short descriptiontext

Exalenz Bioscience is an Israeli diagnostic company that developed the BreathID urea breath test platform for non-invasive Helicobacter pylori detection. Founded in 2006 and now a subsidiary of Meridian Bioscience, it serves gastroenterologists, primary care physicians, and hospital laboratories worldwide.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersUnion, United States
HQ citystring
Union
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
urea breath testing, H. pylori detection, diagnostic platforms, non-invasive diagnostics, gastrointestinal testing
Industry2 codes
PRIMARYHLAHACAD
Blood Oxygen & Respiratory Monitoring (Pulse Oximetry, Capnography, Spirometry)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLAHAGAI
Respiratory Monitoring & Oximetry (Capnography, Pulse Oximeters, Respiratory Rate)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Gastrointestinal Diagnostic Platforms
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1BreathID
Description

Urea breath testing platform for H. pylori detection, includes BreathID Hp Lab, BreathID Smart, and BreathID Hp products

meridianbioscience.com
Core offering1 text field

Exalenz Bioscience develops and commercializes the BreathID System, a urea breath test platform for non-invasive detection of Helicobacter pylori (H. pylori) infections. The platform is offered in three configurations — BreathID Hp Lab, BreathID Smart, and BreathID Hp — designed for clinical laboratory and point-of-care settings to support H. pylori diagnosis and post-treatment retesting.

Differentiator
Functional benefit
Problem solved
Product and service2 records
1BreathID® Hp Lab
CategoryUrea Breath Test Platform
Description

A diagnostic platform for non-invasive detection of Helicobacter pylori (H. pylori) infection using urea breath test technology, configured for laboratory settings.

2BreathID® Smart
No data
Peers10 records
TypeDirect peer
Description

Kibion, now owned by Otsuka, is the most direct competitor to Exalenz, marketing the Heliprobe and Diabact UBT urea breath test systems for H. pylori detection; targeting the same gastroenterology and primary care customers with a near-identical diagnostic modality.

TypeEmerging player
Description

QIAGEN's molecular diagnostics portfolio includes H. pylori PCR-based stool assays that compete with Exalenz's UBT approach as laboratories shift toward molecular, multiplex GI panels.

TypeBroad incumbent
Description

DiaSorin is a larger in-vitro diagnostics company that markets H. pylori stool antigen and serology assays, offering gastroenterologists an alternative non-invasive test modality versus Exalenz's UBT approach.

TypeBroad incumbent
Description

Meridian Bioscience is Exalenz's parent company and the operator of the BreathID line, but it is also a peer in H. pylori diagnostics via its stool antigen, immunoassay, and broader GI pathogen test portfolio targeting the same clinical accounts.

TypeOthers
Description

Bio-Rad supplies immunoassay reagents and quality controls used by clinical labs running H. pylori serology testing, making it an adjacent peer that benefits from the same non-invasive H. pylori diagnostic workflow Exalenz competes in.

TypeDirect peer
Description

EKF Diagnostics markets the BreathTest and associated H. pylori urea breath test devices and consumables, directly competing with Exalenz's BreathID platform in hospital lab and point-of-care settings.

TypeBroad incumbent
Description

Thermo Fisher's diagnostics division offers H. pylori immunoassays and molecular assays, competing for the same non-invasive testing volume that Exalenz targets with the BreathID platform.

TypeDirect peer
Description

Biohit sells the GastroPanel blood-based H. pylori diagnostic and other GI tests, competing for the same gastroenterologist and primary care budgets as Exalenz's urea breath tests.

TypeBroad incumbent
Description

QuidelOrtho markets a portfolio of immunoassay and rapid infectious disease diagnostics, including H. pylori tests that overlap with the diagnostic use cases served by Exalenz's urea breath platforms.

10Abbott Diagnostics
TypeBroad incumbent
Description

Abbott offers broad infectious disease and GI diagnostics, including H. pylori serology and stool antigen assays that compete with UBT-based testing for hospital laboratory and physician office demand.

Market position
Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Exalenz Bioscience

Gastrointestinal Diagnostic Platformsexalenz.com

Exalenz Bioscience is an Israeli diagnostic company that developed the BreathID urea breath test platform for non-invasive Helicobacter pylori detection. Founded in 2006 and now a subsidiary of Meridian Bioscience, it serves gastroenterologists, primary care physicians, and hospital laboratories worldwide.

Exalenz Bioscience firmographics

Firmographics
Name
Exalenz Bioscience
Legal name
Exalenz Bioscience Ltd.
Website
https://exalenz.com
Company type
Private
Founded year
2006
Operating status
Acquired
Headcount range
11–50 employees
Short description
Exalenz Bioscience is an Israeli diagnostic company that developed the BreathID urea breath test platform for non-invasive Helicobacter pylori detection. Founded in 2006 and now a subsidiary of Meridian Bioscience, it serves gastroenterologists, primary care physicians, and hospital laboratories worldwide.
Ownership category
akta.pro rank

Exalenz Bioscience industry classification

Industry
Product category
Gastrointestinal Diagnostic Platforms
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHACAD
Blood Oxygen & Respiratory Monitoring (Pulse Oximetry, Capnography, Spirometry)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLAHAGAI
Respiratory Monitoring & Oximetry (Capnography, Pulse Oximeters, Respiratory Rate)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices

Keywords

  • Urea breath testing
  • H. pylori detection
  • Diagnostic platforms
  • Non-invasive diagnostics
  • Gastrointestinal testing

Where Exalenz Bioscience is headquartered

Location

Headquarters

HQ city
Union
HQ country
United States
HQ region
North America

Markets served

Exalenz Bioscience business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales

Distribution channels2 records

Marketing channels5 records

Exalenz Bioscience product offering

Product offering

Core offering

Exalenz Bioscience develops and commercializes the BreathID System, a urea breath test platform for non-invasive detection of Helicobacter pylori (H. pylori) infections. The platform is offered in three configurations — BreathID Hp Lab, BreathID Smart, and BreathID Hp — designed for clinical laboratory and point-of-care settings to support H. pylori diagnosis and post-treatment retesting.

Differentiator

Problem solved

Functional benefit

Brands

  • BreathID: Urea breath testing platform for H. pylori detection, includes BreathID Hp Lab, BreathID Smart, and BreathID Hp products

Products and services

  • BreathID® Hp Lab A diagnostic platform for non-invasive detection of Helicobacter pylori (H. pylori) infection using urea breath test technology, configured for laboratory settings.
  • BreathID® Smart

Companies that use Exalenz Bioscience

Customer profile

Segments1 record

Ideal customer profiles1 record

Exalenz Bioscience technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Exalenz Bioscience competitors and assessment

Company assessment

Direct peers

  • Kibion (Otsuka Pharmaceutical): Kibion, now owned by Otsuka, is the most direct competitor to Exalenz, marketing the Heliprobe and Diabact UBT urea breath test systems for H. pylori detection; targeting the same gastroenterology and primary care customers with a near-identical diagnostic modality.
  • EKF Diagnostics: EKF Diagnostics markets the BreathTest and associated H. pylori urea breath test devices and consumables, directly competing with Exalenz's BreathID platform in hospital lab and point-of-care settings.
  • Biohit Oyj: Biohit sells the GastroPanel blood-based H. pylori diagnostic and other GI tests, competing for the same gastroenterologist and primary care budgets as Exalenz's urea breath tests.

Emerging players

  • QIAGEN: QIAGEN's molecular diagnostics portfolio includes H. pylori PCR-based stool assays that compete with Exalenz's UBT approach as laboratories shift toward molecular, multiplex GI panels.

Broad incumbents

  • DiaSorin: DiaSorin is a larger in-vitro diagnostics company that markets H. pylori stool antigen and serology assays, offering gastroenterologists an alternative non-invasive test modality versus Exalenz's UBT approach.
  • Meridian Bioscience: Meridian Bioscience is Exalenz's parent company and the operator of the BreathID line, but it is also a peer in H. pylori diagnostics via its stool antigen, immunoassay, and broader GI pathogen test portfolio targeting the same clinical accounts.
  • Thermo Fisher Scientific (Diagnostics): Thermo Fisher's diagnostics division offers H. pylori immunoassays and molecular assays, competing for the same non-invasive testing volume that Exalenz targets with the BreathID platform.
  • QuidelOrtho: QuidelOrtho markets a portfolio of immunoassay and rapid infectious disease diagnostics, including H. pylori tests that overlap with the diagnostic use cases served by Exalenz's urea breath platforms.
  • Abbott Diagnostics: Abbott offers broad infectious disease and GI diagnostics, including H. pylori serology and stool antigen assays that compete with UBT-based testing for hospital laboratory and physician office demand.

Others

  • Bio-Rad Laboratories: Bio-Rad supplies immunoassay reagents and quality controls used by clinical labs running H. pylori serology testing, making it an adjacent peer that benefits from the same non-invasive H. pylori diagnostic workflow Exalenz competes in.

Market position

Customer concentration

Exalenz Bioscience social profiles

Digital presence

Exalenz Bioscience financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Exalenz Bioscience leadership team

Management profile

Number of profiles

Profiles1 record

Exalenz Bioscience funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Exalenz Bioscience M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Exalenz Bioscience

What does Exalenz Bioscience do?

Exalenz Bioscience develops and commercializes the BreathID System, a urea breath test platform for non-invasive detection of Helicobacter pylori (H. pylori) infections. The platform is offered in three configurations — BreathID Hp Lab, BreathID Smart, and BreathID Hp — designed for clinical laboratory and point-of-care settings to support H. pylori diagnosis and post-treatment retesting.

Is Exalenz Bioscience a public or private company?

Exalenz Bioscience is a private company. It is classified as corporate owned and is currently acquired.

When was Exalenz Bioscience founded?

Exalenz Bioscience was founded in 2006. It employs 11 to 50 people.

Where is Exalenz Bioscience based?

Exalenz Bioscience is headquartered in Union, United States, in the North America region.

Who are Exalenz Bioscience's main competitors?

Direct peers on record are Kibion (Otsuka Pharmaceutical), EKF Diagnostics and Biohit Oyj. QIAGEN is listed as an emerging player. Broad incumbents are DiaSorin, Meridian Bioscience, Thermo Fisher Scientific (Diagnostics), QuidelOrtho and Abbott Diagnostics. Bio-Rad Laboratories is listed as an others.

Does Exalenz Bioscience have an API?

No public API is recorded for Exalenz Bioscience.

What industry is Exalenz Bioscience in?

Exalenz Bioscience's product category is Gastrointestinal Diagnostic Platforms. Its primary akta.pro industry code is HLAHACAD, Blood Oxygen & Respiratory Monitoring (Pulse Oximetry, Capnography, Spirometry), with a secondary code of HLAHAGAI, Respiratory Monitoring & Oximetry (Capnography, Pulse Oximeters, Respiratory Rate). Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobesExalenz Bioscience sold at NIS 165m valuationExalenz Bioscience agreed to be sold to a US investor at NIS 6.10 per share, a 70% premium on the opening price, valuing the company at NIS 165 million. The sale price is 97% lower than the 2007 IPO price, and controlling shareholder Mori Arkin will lose at least $10 million.CTechBiomed Entrepreneur Mori Arkin Nearing Sale of Exalenz to a U.S. CompanyMori Arkin is in advanced negotiations to sell his Tel Aviv-listed Exalenz to an unnamed U.S. company. The company has lost 73% of its valuation over five years, but the deal is expected to net Arkin several tens of millions of dollars. Exalenz traded 9.4% up on Tuesday.GlobesExalenz Bioscience seeks buyerExalenz Bioscience, controlled by Mori Arkin, hired an investment bank to manage a sale after its Nasdaq offering was postponed. The company lowered its 2019 sales guidance to $14-15 million, and Arkin aims to sell it for $60 million, more than triple its current market cap.PR NewswireExalenz Bioscience Receives Approval for Commercial Marketing in China for Its BreathID® Hp Lab SystemExalenz Bioscience has received authorization from the China Food and Drug Administration to market its BreathID® Hp Lab System for detecting H. pylori bacteria in China. The company plans to commence sales in the fourth quarter of 2019, targeting hospitals with high-volume testing needs in a market with one of the world's highest prevalences of the bacteria.GlobeNewswireData Collected by Exalenz Bioscience in Galectin Therapeutics’ Phase 2 NASH-CX Trial of GR-MD-02 to Be Presented at AASLD Annual MeetingGalectin Therapeutics announced that an abstract on Exalenz Bioscience's MBT test predicting decompensation in NASH cirrhotics will be presented at the AASLD meeting. The data from 160 patients showed MBT strongly predicts liver decompensation, suggesting it may be more effective than MELD.GlobesExalenz Bioscience raises NIS 15.6m in Tel AvivExalenz Bioscience raised NIS 15.6 million on the TASE, with Mori Arkin spending NIS 7.2 million. The company lowered its guidance due to slower LabCorp adoption, leaving cash at $1.8 million. It still plans a Nasdaq offering.Business Wire BlogExalenz Bioscience Launches Automated BreathID® Hp Lab Urea Breath Testing System For Helicobacter pylori DetectionExalenz Bioscience introduced the BreathID Hp Lab automated urea breath testing system at the 2017 AACC meeting in San Diego. The system automates batch testing for H. pylori detection, building on its point-of-care device's 99% sensitivity and specificity. The company cites expanding clinical guidelines for H. pylori screening.GlobesExalenz Bioscience raises NIS 23.5m in TASE offeringExalenz Bioscience raised NIS 23.5 million in a rights offering, with 94.2% of rights realized, mostly by Mori Arkin. The company's H. pylori breath test trial was successful, and it plans to submit results to the FDA in August, expecting a reply by year-end. The test market generates $30-40 million annually, with Exalenz holding about 10% share.PR NewswireExalenz Biosciences Announces Collaboration with ALF Study Group to use BreathID® to Monitor Patients with Acute Liver FailureExalenz Bioscience announced a collaboration with the Acute Liver Failure Study Group (ALFSG) to conduct a multicenter clinical study evaluating the BreathID® Methacetin Breath Test for predicting patient outcomes in Acute Liver Failure. The FDA-approved study, led by Professor William M. Lee from UT Southwestern Medical Center, will recruit up to 200 patients over two years at 12 sites across the USA and is supported by the National Institute of Diabetes and Digestive and Kidney Diseases. Exalenz will supply BreathID® devices and test kits as part of its growing clinical pipeline targeting serious liver diseases.